Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Capricor Therapeutics (CAPR) Consolidated Net Income (2016 - 2025)

Capricor Therapeutics has reported Consolidated Net Income over the past 15 years, most recently at -$27.1 million for Q4 2025.

  • For Q4 2025, Consolidated Net Income fell 287.11% year-over-year to -$27.1 million; the TTM value through Dec 2025 reached -$101.9 million, down 152.44%, while the annual FY2025 figure was -$105.0 million, 159.58% down from the prior year.
  • Consolidated Net Income for Q4 2025 was -$27.1 million at Capricor Therapeutics, down from -$24.6 million in the prior quarter.
  • Over five years, Consolidated Net Income peaked at -$829093.0 in Q4 2023 and troughed at -$27.1 million in Q4 2025.
  • A 5-year average of -$10.7 million and a median of -$7.5 million in 2022 define the central range for Consolidated Net Income.
  • Biggest five-year swings in Consolidated Net Income: skyrocketed 89.21% in 2023 and later tumbled 745.46% in 2024.
  • Year by year, Consolidated Net Income stood at -$6.4 million in 2021, then fell by 20.79% to -$7.7 million in 2022, then skyrocketed by 89.21% to -$829093.0 in 2023, then tumbled by 745.46% to -$7.0 million in 2024, then crashed by 287.11% to -$27.1 million in 2025.
  • Business Quant data shows Consolidated Net Income for CAPR at -$27.1 million in Q4 2025, -$24.6 million in Q3 2025, and -$25.9 million in Q2 2025.